M. ALADAĞ Et Al. , "Long-term efficacy of combination therapy with PEG-IFN and entecavir on HBsAg loss and anti-HBs seroconversion in patients with chronic active hepatitis," 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) , vol.56, Massachusetts, United States Of America, 2012
ALADAĞ, M. Et Al. 2012. Long-term efficacy of combination therapy with PEG-IFN and entecavir on HBsAg loss and anti-HBs seroconversion in patients with chronic active hepatitis. 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) , (Massachusetts, United States Of America).
ALADAĞ, M., Aladag, H., Harputluoglu, M., SEÇKİN, Y., BİLGİÇ, Y., & KARINCAOĞLU, M., (2012). Long-term efficacy of combination therapy with PEG-IFN and entecavir on HBsAg loss and anti-HBs seroconversion in patients with chronic active hepatitis . 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America
ALADAĞ, MURAT Et Al. "Long-term efficacy of combination therapy with PEG-IFN and entecavir on HBsAg loss and anti-HBs seroconversion in patients with chronic active hepatitis," 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 2012
ALADAĞ, MURAT Et Al. "Long-term efficacy of combination therapy with PEG-IFN and entecavir on HBsAg loss and anti-HBs seroconversion in patients with chronic active hepatitis." 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) , Massachusetts, United States Of America, 2012
ALADAĞ, M. Et Al. (2012) . "Long-term efficacy of combination therapy with PEG-IFN and entecavir on HBsAg loss and anti-HBs seroconversion in patients with chronic active hepatitis." 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) , Massachusetts, United States Of America.
@conferencepaper{conferencepaper, author={MURAT ALADAĞ Et Al. }, title={Long-term efficacy of combination therapy with PEG-IFN and entecavir on HBsAg loss and anti-HBs seroconversion in patients with chronic active hepatitis}, congress name={63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)}, city={Massachusetts}, country={United States Of America}, year={2012}}